预约演示
更新于：2025-07-15
Icosapent Ethyl
二十碳五烯酸乙酯
更新于：2025-07-15
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 日本 (1994-10-05), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C22H34O2 |
InChIKeySSQPWTVBQMWLSZ-AAQCHOMXSA-N |
CAS号86227-47-6 |
关联
56
项与 二十碳五烯酸乙酯 相关的临床试验ISRCTN15140257
Effect of icosapent ethyl on coronary Fat Attenuation Index score in high-risk, statin treated patients with established cardiovascular disease and elevated plasma triglycerides
NCT06710080
Targeting Vascular INflammation in Patients with Community-Acquired Pneumonia (TIN_CAP): a Multi-centre, Prospective, Randomized Control Trial
ISRCTN64669648
Does Vazkepa mitigate the negative effects of metabolic memory in monocyte-derived macrophages isolated from patients with cardiovascular disease +/- type 2 diabetes?
100 项与 二十碳五烯酸乙酯 相关的临床结果
登录后查看更多信息
100 项与 二十碳五烯酸乙酯 相关的转化医学
登录后查看更多信息
100 项与 二十碳五烯酸乙酯 相关的专利（医药）
登录后查看更多信息
1,078
项与 二十碳五烯酸乙酯 相关的文献（医药）2025-09-01Comparative Biochemistry and Physiology D-Genomics & Proteomics
α-Ketoglutarate modulates the mechanisms of toxicity in crucian carp kidneys chronically exposed to NaHCO3: Metabolomics insights
Article
作者: Han, Lin ; Yuan, Fangying ; Liu, Wenzhi ; Liu, Qianwen ; Jin, Xiaofeng ; Cheng, Hongyu ; Sun, Yanchun
Due to the unique physicochemical properties of saline-alkaline water, aquatic organisms find it challenging to survive under such conditions. This study established a freshwater control group (C), a 20 mmol/L NaHCO3 exposure group (T), a 40 mmol/L NaHCO3 exposure group (F), a 20 mmol/L NaHCO3 exposure with α-ketoglutarate (AKG)-supplemented feed group (TA), and a 40 mmol/L NaHCO3 exposure with AKG-supplemented feed group (FA). Histopathological analysis, biochemical assays, and UPLC-QTOF/MS metabolomics were employed to explore the potential mechanisms by which AKG alleviates oxidative damage in freshwater teleosts induced by saline-alkaline stress. Histopathological results showed that as the concentration of carbonate alkali exposure increased, the severity of kidney lesions in crucian carp (Carassius auratus) worsened. However, in the TA and FA groups, the damage showed varying degrees of repair, with the kidney tissue morphology in the TA group almost restored to the state of the C group. Under carbonate alkali exposure, compared to the C group, the activity of antioxidant enzymes Catalase and Superoxide dismutase in crucian carp kidneys decreased in a dose-dependent manner, but increased upon AKG supplementation. Conversely, the levels of Malondialdehyde, blood ammonia, Urea nitrogen, and Uric acid showed the opposite trend. Metabolomics analysis revealed that carbonate-alkali stress caused a series of metabolic disruptions in fish, including amino acid metabolism, lipid metabolism, and energy metabolism. AKG positively regulated metabolic pathways such as the pentose phosphate pathway, arachidonic acid metabolism, and amino acid metabolism, thereby enhancing the antioxidant, anti-inflammatory, and immune capabilities of fish under saline-alkaline stress, alleviating oxidative damage induced by the stress. Overall, our research indicates that saline-alkaline stress significantly alters kidney function and metabolic characteristics, disrupts the antioxidant system and energy homeostasis, inhibits protein catabolism, and induces kidney damage in crucian carp. Exogenous AKG supplementation effectively mitigates oxidative damage and metabolic disorders in crucian carp kidneys under carbonate-alkaline stress. This study elucidates the physiological mechanisms by which AKG alleviates kidney tissue damage under saline-alkaline stress at the metabolic level, providing scientific evidence for the development of aquaculture in saline-alkaline water.
2025-09-01Epilepsy & Behavior Reports
Reduced VNS settings paradoxically decreases seizure burden in a patient following resolution of sleep disordered breathing
Article
作者: Stainman, Rebecca S ; Carosella, Christopher M ; Sponaugle, Austin
Vagus nerve stimulation (VNS) can be a highly effective treatment option for patients with drug resistant epilepsy. Notably, VNS has demonstrated side effects including a unique form of sleep disordered breathing known as vagus nerve stimulator associated sleep disordered breathing (VaS). However, the ways in which VaS interacts with seizure frequency is unknown. We report a case of a 28-year-old woman who presented to our department with complaints of worsening sleep quality 3 years following VNS implantation. Upon polysomnographic (PSG) evaluation, it was discovered that she suffered from VaS. The patient's VNS output current was then down titrated during a subsequent PSG resulting in resolution of her VaS. Interestingly, despite downward titration of her nighttime VNS output current, the patient demonstrated a prolonged seizure free period, highlighting the complex interactions between VNS, VaS and seizure frequency. In cases where patients present with both epilepsy and VaS, physicians should be aware of this complex relationship. Further, this case highlights that down titration of VNS settings may result in not just improvement in VaS but may also result in improvement in seizure frequency.
2025-07-01Developmental Neurobiology
The Impact of Vitamin A Deficiency and Supplementation on Behavioral and Oxidative Stress Markers in Male Offspring of a Valproic Acid‐Induced Autism Rat Model
Article
作者: Laila, Ibouzineddine ; Ezzahra, Kacimi Fatima ; Hicham, Berrougui ; Fatima‐Zahra, Azzaoui ; Soumia, Ed‐Day ; Mhamed, Ramchoun ; Samira, Boulbaroud ; Habiba, Nechchadi
ABSTRACT:
Autism spectrum disorder (ASD) is a neurodevelopmental condition influenced by genetic and environmental factors, including prenatal nutrition. This study investigates the role of Vitamin A deficiency (VAD) in exacerbating ASD‐like behaviors in a valproic acid (VPA)‐induced rat model and mitigating effects of Vitamin A supplementation (VAS). Twenty‐five pregnant rats were divided into five groups, with treatments including VPA exposure and VAD. Neurodevelopmental and behavioral tests, such as the rollover, negative geotaxis, gait, and open field, assessed motor coordination and social interaction in offspring. VPA and VAD groups showed impaired behaviors, motor deficits, and elevated oxidative stress, marked by reduced superoxide dismutase, catalase, and glutathione levels, alongside increased malondialdehyde, nitrite oxide, and altered acetylcholine activity. VAS partially restored antioxidant defenses and alleviated behavioral symptoms. These findings highlight the exacerbating impact of VAD on ASD‐like behaviors and the therapeutic potential of VAS in managing neurodevelopmental and biochemical alterations linked to ASD.
100 项与 二十碳五烯酸乙酯 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 糖尿病 | 韩国 | 2025-05-22 | |
| 疼痛 | 韩国 | 2022-02-21 | |
| 溃疡 | 韩国 | 2022-02-21 | |
| 心血管疾病 | 美国 | 2019-12-13 | |
| 高甘油三酯血症 | 美国 | 2012-07-26 | |
| 动脉硬化闭塞症 | 日本 | 1998-10-15 | |
| 高脂血症 | 日本 | 1994-10-05 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 结肠癌 | 临床3期 | 英国 | 2018-05-02 | |
| 肝转移 | 临床3期 | 英国 | 2018-05-02 | |
| 亨廷顿舞蹈病 | 临床3期 | 美国 | 2005-09-01 | |
| 亨廷顿舞蹈病 | 临床3期 | 加拿大 | 2005-09-01 | |
| 非酒精性脂肪性肝炎 | 临床2期 | 美国 | 2010-06-01 | |
| 非酒精性脂肪性肝炎 | 临床2期 | 波多黎各 | 2010-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 心血管疾病 LDL-C | 8,175 | (LDL‐C <55 mg/dL) | 遞窪獵憲網廠衊糧築製(網觸鬱醖鏇夢壓醖鏇鹹) = 餘積築憲築鬱選膚艱壓 蓋醖觸鹹繭積鏇遞觸製 (顧醖壓範選廠鏇餘顧憲 ) | 积极 | 2025-02-19 | |
Placebo (LDL‐C <55 mg/dL) | 遞窪獵憲網廠衊糧築製(網觸鬱醖鏇夢壓醖鏇鹹) = 淵簾襯觸憲願繭夢鏇衊 蓋醖觸鹹繭積鏇遞觸製 (顧醖壓範選廠鏇餘顧憲 ) | ||||||
临床2/3期 | 131 | (Icosapent Ethyl (IPE)) | 遞艱築鬱網觸壓糧鏇選(窪艱範襯醖構壓糧簾窪) = 築鹹範夢製鏇獵夢築餘 糧鬱糧鬱築膚簾鏇觸衊 (膚鑰襯遞糧鹽選積繭顧, 14.6) 更多 | - | 2024-11-26 | ||
gel cap placebo (Placebo) | 遞艱築鬱網觸壓糧鏇選(窪艱範襯醖構壓糧簾窪) = 壓醖淵鹹襯遞範鹽餘選 糧鬱糧鬱築膚簾鏇觸衊 (膚鑰襯遞糧鹽選積繭顧, 14.1) 更多 | ||||||
临床1/2期 | 1 | Dasatinib+EPA | 築遞齋膚獵築獵遞廠糧(糧壓觸憲積蓋鑰壓選積) = 範顧蓋夢顧淵築範繭蓋 廠製艱鬱獵築鑰繭鑰遞 (衊鹽壓顧壓齋遞鹽積夢, 憲遞夢艱製顧襯觸鹹艱 ~ 壓衊鏇鹽鏇築鑰鑰構餘) 更多 | - | 2024-09-04 | ||
N/A | - | - | 築鹽壓選繭製壓艱觸觸(鏇淵網窪鏇衊鏇餘構繭) = 獵夢壓窪範膚鏇醖顧範 鏇製製積憲鹽鬱選築夢 (窪鹽簾願膚遞鬱簾鹹餘 ) | - | 2024-08-30 | ||
Placebo | 築鹽壓選繭製壓艱觸觸(鏇淵網窪鏇衊鏇餘構繭) = 選鹹顧簾鹹鏇遞夢鹽窪 鏇製製積憲鹽鬱選築夢 (窪鹽簾願膚遞鬱簾鹹餘 ) | ||||||
临床3期 | - | Icosapent Ethyl (IPE) (Lp(a) ≥50 mg/dL) | 製築遞壓蓋獵願簾糧壓(艱範網淵選憲簾廠遞選) = 遞顧鏇艱積構鹽鑰膚築 夢選鑰衊範製壓顧膚壓 (獵選繭蓋簾艱蓋餘範醖 ) 更多 | 积极 | 2024-04-06 | ||
Icosapent Ethyl (IPE) (Lp(a) <50 mg/dL) | 製築遞壓蓋獵願簾糧壓(艱範網淵選憲簾廠遞選) = 遞襯顧鏇網獵築網衊夢 夢選鑰衊範製壓顧膚壓 (獵選繭蓋簾艱蓋餘範醖 ) 更多 | ||||||
临床3期 | - | 3,146 | 築顧願鬱範積簾鬱鏇衊(蓋鹽選積鏇構鑰積網網) = 鏇蓋窪衊築獵襯窪鹽獵 範選壓憲鏇蓋顧鹽範蓋 (膚窪繭願淵蓋鏇築壓構 ) 更多 | - | 2024-01-02 | ||
临床3期 | 2,866 | 繭鹹齋築鏇鑰餘衊窪壓(壓範蓋壓簾範範廠餘鹹): relative risk reduction = 29, P-Value = <0.0001; absolute risk reduction = 5.9 更多 | 积极 | 2023-11-12 | |||
placebo | |||||||
临床3期 | 8,179 | 網餘鬱鑰鏇築憲構壓簾(鬱鏇餘網觸願鹽繭膚鹹) = 窪鏇網範艱艱範簾築壓 築積憲糧膚夢積衊鹹簾 (壓憲艱衊齋積鹹製網憲 ) | 积极 | 2023-11-03 | |||
临床3期 | - | - | 獵網鏇壓壓積壓簾願淵(遞鑰觸憲選醖製衊遞蓋) = 醖齋願鹽鹽衊範醖範襯 鏇構淵廠蓋顧夢醖製願 (窪齋願鏇構選鏇醖選窪, 1.8 ~ 8.7) | - | 2023-08-27 | ||
Placebo | 獵網鏇壓壓積壓簾願淵(遞鑰觸憲選醖製衊遞蓋) = 夢壓鹽夢襯蓋選鹹繭範 鏇構淵廠蓋顧夢醖製願 (窪齋願鏇構選鏇醖選窪, 1.9 ~ 9.4) | ||||||
临床3期 | 8,179 | 壓齋顧鬱顧網鏇獵遞壓(齋積觸襯簾簾襯壓遞蓋) = 築壓餘觸鹹憲糧顧鬱選 憲夢淵壓顧構選鏇襯網 (選餘餘積簾顧鹹襯繭網 ) | - | 2023-02-21 | |||
Placebo | 壓齋顧鬱顧網鏇獵遞壓(齋積觸襯簾簾襯壓遞蓋) = 鏇餘鬱襯簾蓋窪醖觸鑰 憲夢淵壓顧構選鏇襯網 (選餘餘積簾顧鹹襯繭網 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用